---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071517"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:19:43.194128+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026

## Summary
- Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.
- Cash $2.0B; 2026 GAAP op expenses guided $1.6-$1.7B with $180-$200M stock comp.
- Phase 3 RASolute 302 (daraxonrasib in 2L PDAC) readout expected H1 2026; enrollment complete.
- Initiated RASolute 305 (zoldonrasib in 1L PDAC); zoldonrasib FDA Breakthrough Therapy in NSCLC.
- New RAS(ON) inhibitor RMC-5127 entered clinic; new class RM-055 Phase 1 planned Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-071517
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/0001193125-26-071517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/rvmd-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071517
- JSON: https://secwatch.observer/filing/0001193125-26-071517.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.